J0911 HCPCS Level II code: Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)
J0911 is the HCPCS code for “Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J0911Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)
Short description: Inst tauro 1.35mg/hep 100u
HCPCS · United States
Medicare details
The indicators CMS publishes with J0911 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- ESRD supplies
- BETOS category
- Dialysis services (Medicare fee schedule)
- Added
- Jul 1, 2024
Where J0911 sits
- 1J codesDrugs administered other than orally
- 2Active code J0911Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J0911 mean?
J0911 is the HCPCS code for “Instillation, taurolidine 1.35 mg and heparin sodium 100 units (central venous catheter lock for adult patients receiving chronic hemodialysis)” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J0911?
CMS lists J0911’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J0911
All J codesJ0896Injection, luspatercept-aamt, 0.25 mgJ0897Injection, denosumab, 1 mgJ0898Injection, argatroban (auromedics), not therapeutically equivalent to j0883, 1 mg (for non-esrd use)J0899Injection, argatroban (auromedics), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis)J0900Injection, testosterone enanthate and estradiol valerate, up to 1 ccJ0901Vadadustat, oral, 1 mg (for esrd on dialysis)J0945Injection, brompheniramine maleate, per 10 mgJ1000Injection, depo-estradiol cypionate, up to 5 mgJ1010Injection, methylprednisolone acetate, 1 mgJ1020Injection, methylprednisolone acetate, 20 mgJ1030Injection, methylprednisolone acetate, 40 mgJ1040Injection, methylprednisolone acetate, 80 mg